Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HODO-2224 in Hypertension and Hypercholesterolemia
NCT06646354Phase 3Enrolling by invitation
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ezetimibe, rosuvastatin, candesartan, amlodipine in essential hypertension, hypercholesterolemia, sponsored by Hyundai Pharmaceutical Co., Ltd.. Started Apr 2025; status: enrolling by invitation.
02
Drugs
ezetimiberosuvastatincandesartanamlodipine
03
Conditions
essential hypertensionhypercholesterolemia
Beyond the preview
Go deeper on NCT06646354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646354.